152 / 490
150
SCIENTIFIC PROGRAMME
| PROGRAMME AND EXHIBITION GUIDE
INTERDISCIPLINARY RADIOBIOLOGY
CLINICAL BRACHYTHERAPY PHYSICS
RTT
YOUNG
TUESDAY 3 MAY 2016
150
PROGRAMME
& EXHIBITION GUIDE
ESTRO 33
INTERDISCIPLINARYWITHRADIOBIOLOGYFOCUS
Symposium
NEWCONCEPTS OF TUMOUR RADIORESISTANCE
09:15 - 10:30 | ROOM 2
The session will address tumour radioresistance in relation to cancer stem cells, immunology and next
generation sequencing. The talks will cover: 1) evidence that radiotherapy can cause immunogenic cell
death and that combined radiotherapy and immunotherapy can cause systemic long-term effects.
2) Evidence that cancer stem cells are radioresistant and that DNA damage response inhibitors can
overcome the radioresistance and have therapeutic potential. 3) The potential of molecular profiling by
next-generation sequencing for dissecting mechanisms of resistance to radiotherapy/chemoradiation, as
exemplified by results from a recent multicenter trial in locally advanced head and neck cancer.
Chair: R. Syljuasen (Norway)
Co-chair: R. Santoni (Italy)
09:15 > Radiotherapy combined with immunotherapy: present status and future
perspectives
Speaker: P. Lambin (The Netherlands)
SP-0575
09:40 > The contribution of cancer stem cells to tumour radioresistance
Speaker: A. Chalmers (UK)
SP-0576
10:05 > Novel insights in radioresistance of head and neck cancer
Speaker: I. Tinhofer-Keilholz (Germany)
SP-0577
Symposium with Proffered Papers
TOWARDS PERSONALISED RADIATION ONCOLOGY (PRO)
09:15 - 10:30 | ISTANBUL
Personalised Radiation Oncology (PRO), integrating omics technology, is a rapidly developing concept
that will have an enormous impact on radiation therapy in the near future. Besides fascinating science
PRO brings also major new challenges before the concept can be successfully translated into the
clinic, e.g. understanding the potential and limitations of modern omics technologies, interpretation of
results and integration with established clinical parameters to personalise treatment. In this session we
will inform and discuss about developments in genomics, results from studies using gene expression
profiles and data integration approaches. We aim for interdisciplinary audience, i.e. the presentations
will be understandable also for non-experts. In addition, we will discuss where we are today (ready for
implementation?) or what needs to be done to accelerate translation of PRO into the clinics.
Chair: D. Zips (Germany)
Co-chair: V. Tombolini (Italy)
09:15 > New technologies for genomic tumour profiling
Speaker: W. Weichert (Germany)
SP-0578
09:30 > Gene expression profiles in tumours for PRO
Speaker: J. Alsner (Denmark)
SP-0579